Insider Trading Alert - ABMD, WWWW And MSON Traded By Insiders - TheStreet

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 26, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.27 to $2,046,500.00.

Highlighted Stocks Traded by Insiders:

Abiomed (ABMD) - FREE Research Report

Austen W Gerald, who is Director at Abiomed, sold 6,000 shares at $60.62 on Feb. 26, 2015. Following this transaction, the Director owned 83,341 shares meaning that the stake was reduced by 6.72% with the 6,000-share transaction.

The shares most recently traded at $61.12, up $0.50, or 0.82% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares sold: 41,275

The average volume for Abiomed has been 459,700 shares per day over the past 30 days. Abiomed has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 60.27% year-to-date as of the close of trading on Thursday.

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 136.8. Currently, there are 4 analysts who rate Abiomed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Abiomed Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Web.com Group (WWWW) - FREE Research Report

Teichman Jason, who is Chief Operating Officer at Web.com Group, sold 32,600 shares at $17.84 on Feb. 26, 2015. Following this transaction, the Chief Operating Officer owned 116,956 shares meaning that the stake was reduced by 21.8% with the 32,600-share transaction.

The shares most recently traded at $18.02, up $0.18, or 1% since the insider transaction. Historical insider transactions for Web.com Group go as follows:

  • 4-Week # shares bought: 480,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 480,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 693,358
  • 24-Week # shares sold: 20,000

The average volume for Web.com Group has been 599,600 shares per day over the past 30 days. Web.com Group has a market cap of $938.2 million and is part of the technology sector and internet industry. Shares are down 5% year-to-date as of the close of trading on Thursday.

Web.com Group, Inc. provides Internet services to small businesses in North America, South America, and the United Kingdom. The company offers a range of Web services and products that enable small businesses to establish, maintain, promote, and optimize their online presence. Currently, there are 4 analysts who rate Web.com Group a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WWWW - FREE

TheStreet Quant Ratings

rates Web.com Group as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full

Web.com Group Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Misonix (MSON) - FREE Research Report

Oneill Thomas F, who is Director at Misonix, sold 5,000 shares at $11.18 on Feb. 26, 2015. Following this transaction, the Director owned 6,300 shares meaning that the stake was reduced by 44.25% with the 5,000-share transaction.

The shares most recently traded at $12.20, up $1.02, or 8.38% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 45,000
  • 4-Week # shares sold: 54,475
  • 12-Week # shares bought: 45,000
  • 12-Week # shares sold: 54,475
  • 24-Week # shares bought: 47,500
  • 24-Week # shares sold: 80,894

The average volume for Misonix has been 24,300 shares per day over the past 30 days. Misonix has a market cap of $86.1 million and is part of the health care sector and health services industry. Shares are down 0.65% year-to-date as of the close of trading on Thursday.

Misonix, Inc., a surgical device company, designs, develops, manufactures, and markets minimally invasive ultrasonic surgical device products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications. The company has a P/E ratio of 30.5. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings

rates Misonix as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Misonix Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null